Nurix Therapeutics Inc
NRIX
Health Care
2
exclusion reasons
1 theme
This page is part of our public exclusion list — a transparency tool that shows which companies we screen out and why. It is not investment advice, and it is not an accusation. But it is subject to change as our understanding of the facts evolves.
Nurix Therapeutics is a biopharmaceutical company whose drug discovery and development pipeline relies on animal testing. The company's research into targeted protein modulation to treat cancer and autoimmune diseases involves preclinical studies using animal models. While specific revenue percentages from animal-tested products are not publicly broken out, this research method is central to the company's core business of bringing new therapies to market.
A 2023 investigation by Cruelty Free Investors documented animal welfare concerns linked to Nurix's research. The report highlighted a case where a former Tufts School of Medicine faculty member, who later worked at Nurix, was suspended from animal research following allegations of abuse. This individual is listed in professional networks as a scientist at Nurix Therapeutics. The company has not published a formal animal testing policy or committed to adopting alternative research methods.
Nurix Therapeutics is a clinical-stage biopharmaceutical company developing targeted protein degradation therapies, primarily for oncology and inflammatory diseases. The company’s core research and development process, as described in its public SEC filings, relies on animal testing to advance its drug candidates. Nurix explicitly states that its drug candidates have “produced observable results in animal studies” and that it conducts “additional animal studies” concurrent with clinical trials as part of the standard regulatory pathway for drug approval.
The company’s lead programs, including NX-2127, NX-5948, and NRX-0492, are all small-molecule drugs requiring preclinical safety and efficacy testing in animal models before advancing to human trials. This reliance on animal data is a fundamental and non-optional component of its business model, as the company acknowledges that results observed in animals may not translate to humans. As a developer of novel pharmaceutical compounds, Nurix commissions, funds, and requires animal testing as an integral step in its product development pipeline.
Research Sources
8 organizations
Related Exclusions
Wondering what we do invest in?
The Naughty List
A digest of changes to our exclusion list — new additions, removals, and the evidence behind them. We review the list continuously as new evidence surfaces.
Companies appear on our exclusion list based on our investment judgment — not because they've done anything illegal. This is a difference of values and opinion, not an accusation of wrongdoing. Exclusion does not constitute a recommendation against investing in any company, and absence from the list does not constitute a recommendation to invest.
This information is provided for educational and transparency purposes only and should not be relied upon as investment advice. Data is drawn from independent watchdogs, NGOs, government registries, and Ethical Capital's ongoing research — see Research Sources for the full list.
Ethical Capital LLC is a state-registered investment adviser in Utah (CRD #316032). Registration does not imply a certain level of skill or training.